{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:17:35Z","timestamp":1788999455764,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ijid.2022.04.022","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T11:25:35Z","timestamp":1649849135000},"page":"77-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-9579","authenticated-orcid":false,"given":"Andrea","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atil","family":"Saydere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Ungaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Bozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Viero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-4794","authenticated-orcid":false,"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario U.","family":"Mondelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.04.022_bib0001","article-title":"CAR-T cell therapy and infection: a review","volume":"0","author":"Bupha-Intr","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijid.2022.04.022_bib0002","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.04.022_bib0003","doi-asserted-by":"crossref","unstructured":"EMA - European Medicines Agency. SUMMARY OF PRODUCT CHARACTERISTICS Blinatumomab n.d. https:\/\/doi.org\/10.1201\/9780203971093.bmatt.","DOI":"10.1201\/9780203971093.bmatt"},{"key":"10.1016\/j.ijid.2022.04.022_bib0004","doi-asserted-by":"crossref","unstructured":"Europena Medicines Agency. SUMMARY OF PRODUCT CHARACTERISTICS Yescarta n.d. https:\/\/doi.org\/10.2307\/j.ctvdf0dxq.12.","DOI":"10.2307\/j.ctvdf0dxq.12"},{"key":"10.1016\/j.ijid.2022.04.022_bib0005","doi-asserted-by":"crossref","unstructured":"Europena Medicines Agency. SUMMARY OF PRODUCT CHARACTERISTICS Kymriah n.d. https:\/\/doi.org\/10.1201\/9780203971093.bmatt.","DOI":"10.1201\/9780203971093.bmatt"},{"key":"10.1016\/j.ijid.2022.04.022_bib0006","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ijid.2022.04.022_bib0007","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","article-title":"Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy","volume":"146","author":"Fujita","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.ijid.2022.04.022_bib0008","doi-asserted-by":"crossref","first-page":"ofaa126","DOI":"10.1093\/ofid\/ofaa126","article-title":"Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors","volume":"7","author":"Fujita","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2022.04.022_bib0009","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijid.2022.04.022_bib0010","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: an old disease in a new context","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijid.2022.04.022_bib0011","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/apt.15449","article-title":"Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects","volume":"50","author":"Lombardi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijid.2022.04.022_bib0012","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3390\/microorganisms9122460","article-title":"T-Cell Exhaustion in Mycobacterium tuberculosis and Nontuberculous Mycobacteria Infection: Pathophysiology and Therapeutic Perspectives","volume":"9","author":"Lombardi","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijid.2022.04.022_bib0013","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"6","author":"Los-Arcos","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.ijid.2022.04.022_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.04.022_bib0015","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.04.022_bib0016","first-page":"1","author":"Morelli","year":"2021","journal-title":"Infections due to dysregulated immunity\u00a0: an emerging complication of cancer immunotherapy"},{"key":"10.1016\/j.ijid.2022.04.022_bib0017","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijid.2022.04.022_bib0018","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijid.2022.04.022_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.04.022_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2022.04.022_bib0021","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus biTEs: A comparison between T cell\u2013redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijid.2022.04.022_bib0022","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2022.04.022_bib0023","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ijid.2022.04.022_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ijid.2022.04.022_bib0025","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/d41573-019-00090-z","article-title":"The global pipeline of cell therapies for cancer","volume":"18","author":"Xin Yu","year":"2019","journal-title":"Nat Rev Drug Discov"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222002211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222002211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:07:22Z","timestamp":1761120442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222002211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":25,"alternative-id":["S1201971222002211"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.04.022","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}